サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514003

ハンチントン病治療薬の世界市場

Huntington's Disease Therapeutics

出版日
ページ情報
英文 172 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
ハンチントン病治療薬の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 172 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ハンチントン病治療薬の世界市場は2030年までに200億米ドルに達する見込み

2023年に29億米ドルと推定されるハンチントン病治療薬の世界市場は、2030年には200億米ドルに達すると予測され、分析期間2023-2030年のCAGRは31.5%で成長すると予測されます。

米国市場は7億8,760万米ドルと推定、中国はCAGR 40.2％で成長予測

米国のハンチントン病治療薬市場は、2023年に7億8,760万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGRが40.2％で、2030年には予測市場規模が56億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ25.0%と28.3%と予測されています。欧州では、ドイツがCAGR 26.6%で成長すると予測されています。

ハンチントン病治療薬-主要動向と促進要因

ハンチントン病（HD）は、運動機能障害、認知機能低下、精神症状を特徴とする進行性の神経変性疾患です。ハンチントン病は、HTT遺伝子の遺伝子変異によって引き起こされ、異常なハンチンチンタンパク質の産生を引き起こし、脳の特定領域の神経細胞を徐々に損傷します。現在のところ、ハンチントン病の治療法はなく、治療戦略は主に症状の管理と患者のQOLの改善に重点が置かれています。HDの治療薬には、コレア（不随意運動）を抑制するテトラベナジンやドイテトラベナジンなどの運動症状に対する薬剤や、精神症状を抑制する抗精神病薬があります。さらに、抗うつ薬や気分安定薬が、この病気の感情面や行動面に対処するために処方されることも多いです。このような対症療法にもかかわらず、HDの進行を遅らせたり止めたりする疾患修飾療法に対するアンメットニーズは依然として高いです。

ハンチントン病治療薬の研究開発は、遺伝学的・分子生物学的メカニズムの深い理解に牽引され、最近の動向は注目に値します。変異したHTT遺伝子のサイレンシングを目的とした遺伝子治療、有毒なハンチンチンタンパク質の産生を抑えるように設計されたアンチセンス・オリゴヌクレオチド（ASO）、神経細胞の変性に関与する様々な経路を標的とした低分子阻害剤など、革新的な治療アプローチが模索されています。注目すべきは、CRISPR/Cas9のような遺伝子編集技術やRNA干渉（RNAi）療法の臨床試験が進行中で、前臨床試験で有望視されていることです。さらに、幹細胞研究は、損傷したニューロンを置換し、神経機能を回復させる可能性のある戦略として研究されています。これらの最先端の治療法は、まだ実験段階とはいえ、ハンチントン病の経過を変えるための希望に満ちた未来を示しています。

ハンチントン病治療薬市場の成長は、遺伝子研究における技術的進歩、神経変性疾患研究への資金提供の増加、ハンチントン病に対する認識の高まりなど、いくつかの要因によってもたらされます。遺伝子治療やRNAベースの技術の進歩は、単に症状を管理するのではなく、疾患の根本原因をターゲットにした治療法を開発する新たな道を開いた。製薬会社やバイオテクノロジー企業によるHD研究への投資は、潜在的な治療法の開発を加速させ、いくつかの有望な候補が臨床試験を進めています。さらに、患者支援団体や研究組織は、HD研究に対する認識を高め、資金を確保する上で重要な役割を果たしています。また、希少疾病用医薬品や画期的な治療法の承認プロセスの迅速化を目指した取り組みにより、規制当局の環境もより協力的になっています。病気の早期発見や進行のモニタリングにバイオマーカーを使用するなど、診断技術の進歩は、よりタイムリーで的確な治療介入を容易にしています。これらの要因が相まって、ハンチントン病治療薬市場は大きな成長と革新を遂げており、近い将来、より効果的な治療と患者の予後改善が期待されています。

調査対象企業の例（注目の23社）

  • Alnylam Pharmaceuticals, Inc.
  • Evotec AG
  • GlaxoSmithKline PLC
  • Horizon Therapeutics plc
  • Ionis Pharmaceuticals, Inc.
  • Raptor Pharmaceutical Corporation
  • Sangamo Biosciences, Inc.
  • Suven Life Sciences Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc.
  • Wave Life Sciences Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6280

Global Huntington's Disease Therapeutics Market to Reach US$20.0 Billion by 2030

The global market for Huntington's Disease Therapeutics estimated at US$2.9 Billion in the year 2023, is expected to reach US$20.0 Billion by 2030, growing at a CAGR of 31.5% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$787.6 Million While China is Forecast to Grow at 40.2% CAGR

The Huntington's Disease Therapeutics market in the U.S. is estimated at US$787.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.6 Billion by the year 2030 trailing a CAGR of 40.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 25.0% and 28.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 26.6% CAGR.

Huntington's Disease Therapeutics - Key Trends and Drivers

Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. It is caused by a genetic mutation in the HTT gene, leading to the production of an abnormal huntingtin protein that progressively damages neurons in specific regions of the brain. Currently, there is no cure for Huntington’s disease, and treatment strategies are primarily focused on managing symptoms and improving patients' quality of life. Therapeutics for HD include medications for motor symptoms, such as tetrabenazine and deutetrabenazine, which help control chorea (involuntary movements), and antipsychotic drugs to manage psychiatric symptoms. Additionally, antidepressants and mood stabilizers are often prescribed to address the emotional and behavioral aspects of the disease. Despite these symptomatic treatments, there remains a significant unmet need for disease-modifying therapies that can slow or halt the progression of HD.

Research and development in Huntington’s disease therapeutics have made notable advancements in recent years, driven by a deeper understanding of the disease’s genetic and molecular mechanisms. Innovative therapeutic approaches are being explored, including gene therapies aimed at silencing the mutated HTT gene, antisense oligonucleotides (ASOs) designed to reduce the production of the toxic huntingtin protein, and small molecule inhibitors targeting various pathways involved in neuronal degeneration. Notably, clinical trials for gene-editing technologies, such as CRISPR/Cas9, and RNA interference (RNAi) therapies are underway, showing promise in preclinical studies. Furthermore, stem cell research is being investigated as a potential strategy for replacing damaged neurons and restoring neurological function. These cutting-edge therapies, while still in experimental stages, represent a hopeful future for altering the course of Huntington’s disease.

The growth in the Huntington’s disease therapeutics market is driven by several factors, including technological advancements in genetic research, increased funding for neurodegenerative disease research, and a growing awareness of HD. The progress in gene therapy and RNA-based technologies has opened new avenues for developing treatments that target the root cause of the disease rather than just managing symptoms. Investment from pharmaceutical companies and biotech firms into HD research has accelerated the development of potential therapies, with several promising candidates advancing through clinical trials. Additionally, patient advocacy groups and research organizations are playing a crucial role in raising awareness and securing funding for HD research. The regulatory environment is also becoming more supportive, with initiatives aimed at expediting the approval process for orphan drugs and breakthrough therapies. Advances in diagnostic technologies, including the use of biomarkers for early detection and monitoring of disease progression, are facilitating more timely and precise treatment interventions. Collectively, these factors are driving significant growth and innovation in the Huntington’s disease therapeutics market, offering hope for more effective treatments and improved outcomes for patients in the near future.

Select Competitors (Total 23 Featured) -

  • Alnylam Pharmaceuticals, Inc.
  • Evotec AG
  • GlaxoSmithKline PLC
  • Horizon Therapeutics plc
  • Ionis Pharmaceuticals, Inc.
  • Raptor Pharmaceutical Corporation
  • Sangamo Biosciences, Inc.
  • Suven Life Sciences Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc.
  • Wave Life Sciences Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Huntington's Disease Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Genetic Research Throws the Spotlight on Huntington's Disease Therapies
    • Technological Innovations in Gene Therapy Propel Growth in Treatment Options
    • Focus on Neurodegenerative Disease Research Expands Addressable Market Opportunity
    • Development of Antisense Oligonucleotides (ASOs) Strengthens Business Case for Targeted Therapies
    • Emerging RNA Interference (RNAi) Technologies Drives Adoption of Novel Treatment Approaches
    • Promising Results from Stem Cell Research Generates Hope for Neuronal Restoration
    • CRISPR/Cas9 and Gene-Editing Techniques: Here's the Story of Revolutionary Therapeutic Potential
    • Growing Awareness and Advocacy Efforts Spurring Growth in Research and Development
    • Regulatory Initiatives for Orphan Drugs Accelerates Demand for Huntington's Disease Treatments
    • Advances in Biomarker Development Drives Adoption of Early Detection and Monitoring Tools
    • Progress in Disease-Modifying Therapies to Transform Patient Outcomes
    • Expedited Clinical Trials for Breakthrough Therapies Generates Momentum in Market Dynamics
    • Expansion of Early-Stage Clinical Programs: Here's the Story of Future Therapeutic Advancements
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Huntington's Disease Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Huntington's Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • JAPAN
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CHINA
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • EUROPE
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Huntington's Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • GERMANY
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for Huntington's Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 32: Asia-Pacific 16-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • INDIA
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: India Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • LATIN AMERICA
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for Huntington's Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Latin America 16-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MIDDLE EAST
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for Huntington's Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 54: Middle East 16-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • AFRICA
    • Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR

IV. COMPETITION